3014 – NON-CANONICAL EZH2 DRIVES RETINOIC ACID RESISTANCE OF VARIANT ACUTE PROMYELOCYTIC LEUKEMIAS

• Published in: Experimental hematology 2022, Vol.111, p.S51-S51
• Main Authors: Poplineau, Mathilde, Platet, Nadine, Mazuel, Adrien, Hérault, Léonard, Koide, Shuhei, N'guyen, Lia, Iwama, Atsushi, Duprez, Estelle
• Format: Article
• Language: English
• ISSN: 0301-472X; 1873-2399
• DOI: 10.1016/j.exphem.2022.07.070

Cancer cell heterogeneity is a major driver of therapy resistance. To characterize resistant cells and their vulnerabilities, we studied the PLZF-RARA variant of acute promyelocytic leukemia (APL), resistant to retinoic acid (RA), using single-cell multi-omics. We uncovered transcriptional and chromatin heterogeneity in leukemia cells. We identified a subset of cells resistant to RA with proliferation, DNA replication and repair signatures, that depend on a fine-tuned E2F transcriptional network targeting the epigenetic regulator Enhancer of Zeste Homolog 2 (EZH2). Epigenomic and functional analyses validated the driver role of EZH2 in RA resistance. Targeting pan-EZH2 activities (canonical/non-canonical) was necessary to eliminate leukemia relapse initiating cells, which underlies a dependency of resistant cells on an EZH2 non-canonical activity and the necessity to degrade EZH2 to overcome resistance. Our study provides critical insights into the mechanisms of RA resistance that allow us to eliminate treatment-resistant leukemia cells by targeting EZH2, thus highlighting a potential targeted therapy approach. Beyond RA resistance and APL context, our study also demonstrates the power of single-cell multi-omics to identify, characterize and clear therapy-resistant cells.